<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511900</url>
  </required_header>
  <id_info>
    <org_study_id>CAT 1004 102</org_study_id>
    <nct_id>NCT01511900</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAT-1004 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety of escalating multiple doses
      over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D).

      Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of
      escalating multiple doses of CAT-1004 in patients with T2D.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Screening to Follow-up (Day 25)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CAT-1004</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose area under the curve for 0-24 hrs/24 and 0-4 hrs/4</measure>
    <time_frame>Day -2 through f/u (Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CAT-1004</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for hematology, chemistry, coagulation and urinalysis</measure>
    <time_frame>Baseline through End of study (Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for Physical exams</measure>
    <time_frame>Baseline through end of study (Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for ECGs</measure>
    <time_frame>Baseline through end of study (Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Baseline through end of study (Day 25)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose orally: CAT-1004 Dose level 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose orally: CAT-1004 Dose level 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose orally: CAT-1004 Dose level 3 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose orally: CAT-1004 Dose level 4 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Dose level TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose orally: CAT-1004 Dose level TBD or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT 1004</intervention_name>
    <description>Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004</description>
    <arm_group_label>Cohort 1: Dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort</description>
    <arm_group_label>Cohort 1: Dose level 1</arm_group_label>
    <arm_group_label>Cohort 2: Dose level 2</arm_group_label>
    <arm_group_label>Cohort 3: Dose level 3</arm_group_label>
    <arm_group_label>Cohort 4: Dose level 4</arm_group_label>
    <arm_group_label>Cohort 5: Dose level TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT 1004</intervention_name>
    <description>Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004</description>
    <arm_group_label>Cohort 2: Dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT 1004</intervention_name>
    <description>Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004</description>
    <arm_group_label>Cohort 3: Dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT 1004</intervention_name>
    <description>Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004</description>
    <arm_group_label>Cohort 4: Dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT 1004</intervention_name>
    <description>Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004</description>
    <arm_group_label>Cohort 5: Dose level TBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient must meet all of the following criteria to be in the study:

          -  Age between 18 to 65 years inclusive at Screening.

          -  Diagnosis of T2D:

          -  For Part I:

               -  Treated with any diet and exercise, with or without metformin (stable for ≥ 2
                  months).

               -  HbA1c ≥ 7.0% and ≤ 10.0% if on diet and exercise alone, or ≥6.5 % and ≤ 9.0% if
                  on metformin.

          -  For Part II:

             • Stable on metformin for ≥ 2 months with HbA1c ≥ 7.0% and ≤ 10.0%.

          -  Satisfies one of the following:

               -  Females not of childbearing potential: non-pregnant and non-lactating; surgically
                  sterile or postmenopausal for 2 years or at least 1 year with a follicle
                  stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR

               -  Males: surgically sterile, abstinent, or patient or partner is utilizing an
                  acceptable contraceptive method during and 3 months after the last study dose.

          -  On a stable diet with body mass index (BMI): 25 to 40 kg/m2 inclusive at Screening
             with weight stable (± 4 kg) for &gt; 6 weeks prior to Screening.

        Exclusion Criteria:

        A patient will not be eligible if any of the following criteria apply:

          -  Use of prescription medications other than allowed medications within 30 days of
             planned admission to the clinic. Allowed medications include metformin,
             anti-hypertensives, lipid-lowering medications, thyroid replacement therapy, low-dose
             aspirin (81 mg/day), proton pump inhibitors and anti-depressants. Prescribed doses of
             these medications must have been stable for 2 months at the time of first dose.

          -  Clinically significant abnormalities in physical examination or vital signs at
             screening

          -  Clinically significant electrocardiogram (ECG) abnormalities as assessed by the
             investigator.

          -  Clinically significant laboratory result as assessed by the Investigator.

          -  The patient has a history of clinically significant medical disease including
             significant allergies (except for untreated, asymptomatic seasonal allergies at the
             time of dosing), or hematological, endocrine, pulmonary, gastrointestinal,
             cardiovascular, hepatic, psychiatric, or neurological disease, other than T2D,
             hypertension, dyslipidemia, hypothyroidism or depression.

          -  History or presence of malignancy within the past 5 years.

          -  History of Type 1 diabetes or clinically significant cardiovascular disease (including
             a history of unstable angina, acute myocardial infarction, coronary artery bypass
             graft, percutaneous coronary intervention, or New York Heart Association Class III or
             IV congestive heart failure within 6 months prior to screening) or clinically
             significant renal disease.

          -  History of alcohol or substance abuse or eating disorder within 2 years, OR regular
             use of alcohol within 6 months (&gt;14 units of alcohol per week; 1 unit = 150 mL of
             wine, 360 mL of beer, or 45 mL of 40% alcohol).

          -  Use of any investigational drug or participation in any investigational study within
             30 days prior to screening or 5 half-lives of the study agent, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Donovan, M.D., PhD</last_name>
    <role>Study Director</role>
    <affiliation>Catabasis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

